Full Text

Turn on search term navigation

© 2019. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Aim: Evaluation of the Nativis Voyager®, an investigational medical device, as monotherapy for recurrent glioblastoma (rGBM). Materials & methods: A total of 15 patients with rGBM were treated with one of two Voyager ultra-low radio frequency energy cognates: A1A or A2HU. Safety and clinical utility were assessed every 2–4 months. Results: Median overall survival was 8.04 months in the A1A arm and 6.89 months in the A2HU arm. No serious adverse events associated with Voyager were reported. No clinically relevant trends were noted in clinical laboratory parameters or physical exams. Conclusion: The data suggest that the Voyager is safe and feasible for the treatment of rGBM.

Details

Title
A feasibility study of the Nativis Voyager® device in patients with recurrent glioblastoma in Australia
Author
Murphy, Michael; Dowling, Anthony; Thien, Christopher; Priest, Emma; Donna Morgan Murray; Kesari, Santosh
Section
Clinical Trial Evaluation
Publication year
2019
Publication date
Mar 2019
Publisher
Future Medicine Ltd
ISSN
20450907
e-ISSN
20450915
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2213171666
Copyright
© 2019. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.